Wielgosz M
Zakładu Farmakologii Akademii Medycznej, Lublinie.
Psychiatr Pol. 1992 Sep-Oct;26(5):357-64.
The authors presents the literature concerned with the role of D-1 and D-2 dopamine receptors in the pathogenesis of schizophrenia and the effects of neuroleptics. The author concludes that substances which stimulate the D-1 receptors may decrease symptoms of schizophrenia and restrain the formation of tardive dyskinesia, whilst blocking the D-1 receptors may act anti-psychotically without causing tardive dyskinesia. However, they cannot be used with people because of their considerable toxicity. The introduction of new generation of neuroleptics.
作者介绍了与D1和D2多巴胺受体在精神分裂症发病机制中的作用以及抗精神病药物作用相关的文献。作者得出结论，刺激D1受体的物质可能会减轻精神分裂症的症状并抑制迟发性运动障碍的形成，而阻断D1受体可能具有抗精神病作用且不会引起迟发性运动障碍。然而，由于其相当大的毒性，它们不能用于人体。新一代抗精神病药物的引入。
